Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

248.96 -5.11 (-2.01%)
Streaming Delayed Price Updated: 3:38 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 498,979
Open 253.68
Bid (Size) 248.81 (200)
Ask (Size) 249.10 (160)
Prev. Close 254.07
Today's Range 247.88 - 254.44
52wk Range 197.81 - 495.55
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗
Wall Street expects an even bigger rebound for this beaten-down biotech stock. 
Via The Motley Fool

Performance

YTD
-37.8%
-37.8%
1 Month
+3.4%
+3.4%
3 Month
-17.3%
-17.3%
6 Month
-24.8%
-24.8%
1 Year
-44.4%
-44.4%

More News

Read More
News headline image
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook ↗
Via MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech ↗
Via Chartmill
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Worthy of Investor Attention ↗
Via Chartmill
News headline image
Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial ↗
Via MarketBeat
Topics Death
News headline image
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗
Via The Motley Fool
News headline image
If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗
Via Benzinga
News headline image
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗
Via Benzinga
News headline image
Alnylam Pharmaceuticals, Inc. Investors: Investigation Launched Into Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by Kessler Topaz Meltzer & Check, LLP
Via NewMediaWire
News headline image
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
(NASDAQ: ALNY): Investigation Launched Into Alnylam Pharmaceuticals, Inc. by Kessler Topaz Meltzer & Check, LLP
Via NewMediaWire
News headline image
Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via Business Wire
News headline image
NASDAQ: ALNY: Kessler Topaz Meltzer & Check, LLP Launches Investigation Into Alnylam Pharmaceuticals, Inc.
Via NewMediaWire
News headline image
ALNY ALERT: Investigation Launched Into Alnylam Pharmaceuticals, Inc., Investors Are Encouraged to Contact KTMC Law Firm
Via NewMediaWire
News headline image
ALNY Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
Via NewMediaWire
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
Via The Motley Fool
News headline image
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
News headline image
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Alnylam (ALNY) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 248.96
When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 09/30/26 03:38 PM ET
What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 29.59B
How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
Alnylam Pharmaceuticals, Inc. - Common Stock has 30B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.